CORRECTING and REPLACING HAQ Special Meeting of Stockholders to Vote on Proposed Merger of HAQ and PharmAthene Adjourned to 3 p.
August 02 2007 - 11:32AM
Business Wire
Please replace the release with the following corrected version due
to multiple revisions. The corrected release reads: HAQ SPECIAL
MEETING OF STOCKHOLDERS TO VOTE ON PROPOSED MERGER OF HAQ AND
PHARMATHENE ADJOURNED TO 3 P.M. E.T. THURSDAY, AUG. 2, 2007
Healthcare Acquisition Corp. (AMEX:HAQ), a publicly-traded special
purpose acquisition company, announced that it has convened and
then adjourned without conducting any business, its special meeting
of stockholders to vote on, among other things, the proposed merger
transaction with PharmAthene, Inc., a biodefense company developing
and commercializing medical countermeasures against biological and
chemical threats. The special meeting of stockholders will
reconvene at 3:00 p.m. E.T. on Thursday, August 2nd at the offices
of McCarter & English, LLP, 245 Park Avenue, 27th Floor, New
York, NY. The special meeting has been adjourned in order to
provide HAQ stockholders additional time to consider and vote on
the proposed merger and related proposals. The record date for
stockholders entitled to vote at the special meeting remains the
close of business on June 15, 2007. Definitive proxy materials
relating to the special meeting were filed with the U.S. Securities
and Exchange Commission on July 13, 2007 and such materials were
mailed to HAQ stockholders of record on or about July 16, 2007.
HAQ�s stockholders are urged to read the proxy statement and other
relevant materials if and as they become available, as they will
contain important information about the proposed merger and the
related proposals. The Board of Directors of HAQ unanimously
recommends that stockholders vote �for� each of the proposals
related to the proposed merger transaction. Additional information
about the proposed merger and each of the other proposals can be
found in the definitive proxy statement. HAQ stockholders with
questions about the proposed merger or any of the other proposals
or who need assistance in voting their shares may call the
Company�s proxy solicitor, Morrow & Co., Inc., toll-free at
(800) 607-0088. Additional Information HAQ AND ITS DIRECTORS AND
EXECUTIVE OFFICERS AS WELL AS PHARMATHENE AND ITS DIRECTORS AND
EXECUTIVE OFFICERS MAY BE DEEMED TO BE PARTICIPANTS IN THE
SOLICIATION OF PROXIES FOR THE SPECIAL MEETING OF HAQ�S
STOCKHOLDERS TO BE HELD TO APPROVE THE PROPOSED MERGER.
SECURITYHOLDERS AND OTHER INTERESTED PERSONS ARE URGED TO READ THE
DEFINITIVE PROXY STATEMENT REGARDING THE PROPOSED MERGER FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION ON JULY 13, 2007, AS THEY
CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER.
STOCKHOLDERS WILL ALSO BE ABLE TO OBTAIN A COPY OF THE DEFINITIVE
PROXY STATEMENT, WITHOUT CHARGE, BY DIRECTING A REQUEST TO HAQ AT:
2116 FINANCIAL CENTER, 666 WALNUT STREET, DES MOINES, IOWA 50309.
THE DEFINITIVE PROXY STATEMENT AND THE FINAL PROSPECTUS AND OTHER
SEC FILINGS OF HAQ CAN ALSO BE OBTAINED, WITHOUT CHARGE, AT THE
SECURITIES AND EXCHANGE COMMISSION�S INTERNET SITE
(http://www.sec.gov). HAQ AND PHARMATHENE CLAIM THE PROTECTION OF
THE SAFE HARBOR FOR �FORWARD-LOOKING STATEMENTS� WITHIN THE MEANING
OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT ARE NOT HISTORICAL
FACTS. SUCH FORWARD-LOOKING STATEMENTS, BASED UPON THE CURRENT
BELIEFS AND EXPECTATIONS OF MANAGEMENT OF HAQ AND PHARMATHENE
REGARDING, AMONG OTHER THINGS, THE BUSINESS OF PHARMATHENE AND THE
MERGER, ARE SUBJECT TO RISKS AND UNCERTAINTIES, WHICH COULD CAUSE
ACTUAL RESULTS TO DIFFER FROM THE FORWARD-LOOKING STATEMENTS. RISKS
AND UNCERTAINTIES INCLUDE RISKS ASSOCIATED WITH THE RELIABILITY OF
THE RESULTS OF THE INITIAL WORK CONDUCTED ON VALORTIM� RELATING TO
ANIMAL EFFICACY, HUMAN SAFETY AND LIKELIHOOD OF SUCCESSFUL
DEVELOPMENT OF AN EFFICIENT AND SCALABLE MANUFACTURING PROCESS,
UNEXPECTED FUNDING DELAYS BY NIAID, UNFORESEEN SAFETY ISSUES
RESULTING FROM THE HANDLING OF BACILLUS ANTHRACIS, UNFORESEEN
SAFETY ISSUES RESULTING FROM THE ADMINISTRATION OF VALORTIM�
(MDX-1303) IN HUMAN SUBJECTS, UNCERTAINTIES RELATED TO PRODUCT
MANUFACTURING. THERE CAN BE NO ASSURANCE THAT SUCH DEVELOPMENT
EFFORTS WILL SUCCEED OR THAT OTHER DEVELOPED PRODUCTS WILL RECEIVE
REQUIRED REGULATORY CLEARANCE OR THAT, EVEN IF SUCH REGULATORY
CLEARANCE WERE RECEIVED, SUCH PRODUCTS WOULD ULTIMATELY ACHIEVE
COMMERCIAL SUCCESS. About Healthcare Acquisition Corp. Des
Moines-based Healthcare Acquisition Corp. was jointly formed by
healthcare investing pioneers, John Pappajohn and Derace L.
Schaffer, M.D. Healthcare Acquisition Corp. is a special purpose
acquisition company focused on the healthcare industry. The Company
raised $75.2 million through an IPO in July, 2005. As of March 31,
2007, the Company held approximately $71.4 million in trust. The
Company�s shares trade on the American Stock Exchange, under the
symbol HAQ and its warrants trade on the American Stock Exchange
under the symbol HAQ-WT. About PharmAthene, Inc. PharmAthene, a
privately-held biodefense company, was formed in 2001 to meet the
critical needs of the United States by developing biodefense
products. PharmAthene is dedicated to the rapid development of
important and novel biotherapeutics to address biological pathogens
and chemicals that may be used as weapons of bioterror.
PharmAthene�s lead programs include Valortim� and Protexia�. For
more information on PharmAthene, please visit www.PharmAthene.com.
Healthcare Acquisition (AMEX:HAQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Healthcare Acquisition (AMEX:HAQ)
Historical Stock Chart
From Sep 2023 to Sep 2024